1. Home
  2. MIRM vs SKWD Comparison

MIRM vs SKWD Comparison

Compare MIRM & SKWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MIRM
  • SKWD
  • Stock Information
  • Founded
  • MIRM 2018
  • SKWD 2007
  • Country
  • MIRM United States
  • SKWD United States
  • Employees
  • MIRM N/A
  • SKWD N/A
  • Industry
  • MIRM Biotechnology: Pharmaceutical Preparations
  • SKWD Property-Casualty Insurers
  • Sector
  • MIRM Health Care
  • SKWD Finance
  • Exchange
  • MIRM Nasdaq
  • SKWD Nasdaq
  • Market Cap
  • MIRM 1.9B
  • SKWD 2.0B
  • IPO Year
  • MIRM 2019
  • SKWD 2023
  • Fundamental
  • Price
  • MIRM $39.10
  • SKWD $54.79
  • Analyst Decision
  • MIRM Strong Buy
  • SKWD Buy
  • Analyst Count
  • MIRM 11
  • SKWD 12
  • Target Price
  • MIRM $58.55
  • SKWD $59.13
  • AVG Volume (30 Days)
  • MIRM 476.2K
  • SKWD 521.7K
  • Earning Date
  • MIRM 05-07-2025
  • SKWD 05-01-2025
  • Dividend Yield
  • MIRM N/A
  • SKWD N/A
  • EPS Growth
  • MIRM N/A
  • SKWD 27.90
  • EPS
  • MIRM N/A
  • SKWD 2.87
  • Revenue
  • MIRM $336,888,000.00
  • SKWD $1,150,200,000.00
  • Revenue This Year
  • MIRM $29.51
  • SKWD $16.85
  • Revenue Next Year
  • MIRM $20.27
  • SKWD $12.65
  • P/E Ratio
  • MIRM N/A
  • SKWD $19.09
  • Revenue Growth
  • MIRM 80.76
  • SKWD 29.82
  • 52 Week Low
  • MIRM $23.14
  • SKWD $33.27
  • 52 Week High
  • MIRM $54.23
  • SKWD $55.62
  • Technical
  • Relative Strength Index (RSI)
  • MIRM 34.64
  • SKWD 61.43
  • Support Level
  • MIRM $37.83
  • SKWD $53.33
  • Resistance Level
  • MIRM $40.32
  • SKWD $52.85
  • Average True Range (ATR)
  • MIRM 2.47
  • SKWD 2.70
  • MACD
  • MIRM -0.33
  • SKWD 0.22
  • Stochastic Oscillator
  • MIRM 25.14
  • SKWD 94.31

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About SKWD Skyward Specialty Insurance Group Inc.

Skyward Specialty Insurance Group Inc is a specialty insurance company that delivers commercial property and casualty products and solutions on a non-admitted and admitted basis. The firm has one reportable segment through which it offers a broad array of insurance coverages to several market niches. It operates multiple lines of business, including general liability, excess liability, professional liability, commercial auto, group accident, health, property, surety, and workers' compensation.

Share on Social Networks: